Skip to Content

Isentress (raltegravir) Disease Interactions

There are 4 disease interactions with Isentress (raltegravir):

Moderate

Raltegravir (Includes Isentress) ↔ Hemodialysis

Moderate Potential Hazard, Moderate plausibility

Applies to: hemodialysis

There were no clinically important pharmacokinetic differences between subjects with severe renal impairment and healthy subjects. No dosage adjustment is necessary for these patients. Because the extent to which raltegravir may be dialyzable is unknown, dosing before a dialysis session should be avoided.

Moderate

Raltegravir (Includes Isentress) ↔ Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

There were no clinically important pharmacokinetic differences between subjects with moderate hepatic impairment and healthy subjects. No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. Therapy with raltegravir should be administered with caution in patients with severe hepatic impairment, as the pharmacokinetics of raltegravir have not been studied in this population. Liver transaminases and bilirubin should regularly be monitored during therapy.

Moderate

Raltegravir (Includes Isentress) ↔ Myopathy/Rhabdomyolysis

Moderate Potential Hazard, Moderate plausibility

Applies to: Myopathy

The use of raltegravir has been associated with creatine kinase elevations. There have been reports of myopathy and rhabdomyolysis in patients taking raltegravir. Therapy with raltegravir should be used with caution in patients at increased risk of myopathy or rhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions or patients with a history of rhabdomyolysis, myopathy or increased serum creatine kinase levels.

Moderate

Raltegravir (Includes Isentress) ↔ Pku

Moderate Potential Hazard, Moderate plausibility

Applies to: Phenylketonuria

Isentress (brand of raltegravir) chewable tablets contain phenylalanine. The 25 mg chewable tablet contains approximately 0.05 mg phenylalanine and the 100 mg contains approximately 0.10 mg phenylalanine. The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e. phenylketonuria).

Isentress (raltegravir) drug Interactions

There are 119 drug interactions with Isentress (raltegravir)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide